Enforcement Report - Week of June 14, 2023
Enforcement Report - Week of February 13, 2019
Lexiscan (regadenoson) : Astellas Pharma, Gilead Sciences vs. Apotex
Recipharm appoints Henrik Stenqvist as its new executive VP and chief financial officer, bringing 24 years of finance and management experience.
Mylan will close a manufacturing site in Decatur, Illinois that it gained when it bought Swedish drug maker Meda last year.
Mylan has been in the midst of whacking about 3,500 jobs to cut costs and refocus after its $7 billion buyout last year of Meda Pharmaceuticals. About 90 of those cuts will come with the closure of a plant in Illinois.
Yesterday, MEDA Pharmaceuticals, a subsidiary of Canonsburg, Penn.-based Mylan (MYL), announced it was closing its manufacturing facility in Decatur, Ill. This would result in 90 job cuts.
NEW DELHI: Piramal Enterprises today said it has completed acquisition of a portfolio of drugs for spasticity and pain management from Mallinckrodt LLC.
The company’s moves to “reduce redundancy” will impact “less than 10%” of its global workforce, according to a spokesperson. At of the end of 2015, Mylan employed nearly 35,000 people around the world, meaning the new cuts could affect roughly 3,500 people at the high end.
True, Novartis is having trouble with its Alcon ophthalmology unit and it's been shopping for deals for some time. But generics companies have their own struggles, and building up by dealmaking is one way to combat them.